SAFETY DATA SHEET



Products Containing Dako Antibody Diluent

Section 1. Identification

1.1 Product identifier

Product name

: Products Containing Dako Antibody Diluent

Part no.

ZA051, GA052, GA053, GA054, GA055, GA058, GA059, GA060, GA061, GA062, GA067, GA074, GA075, GA077, GA080, GA084, GA090, GA600, GA750, IC001, IC002, IC004, IK001, IK002, IK004, IR002, IR051, IR052, IR053, IR054, IR055, IR056, IR057, IR058, IR059, IR060, IR061, IR062, IR066, IR067, IR068, IR069, IR072, IR074, IR075, IR076, IR077, IR079, IR080, IR082, IR084, IR085, IR086, IR087, IR088, IR089, IR091, IR092, IR093, IR094, IR600, IR750, IS051, IS052, IS053, IS054, IS055, IS056, IS057, IS059, IS060, IS062, IS067, IS068, IS069, IS072, IS074, IS075, IS077, IS079, IS080, IS082, IS084, IS600, IS750, IX018, IX019, K3954, M0617, M0630, M0633, M0634, M0635, M3501, M3502, M3503, M3504, M3505, M3506, M3512, M3515, M3517, M3525, M3528, M3539, M3556, M3562, M3563, M3567, M3568, M3569, M3571, M3575, M3612, M3614, M3615, M3616, M3617, M3619, M3620, M3621, M3623, M3624, M3625, M3626, M3627, M3628, M3631, M3632, M3636, M3638, M3639, M3640, M3641, M3642, M3643, M3646, M3647, M3649, M3651, M3653, M3666, M7019, M7020, M7191, M7235, M7237, M7240, M7271, M7310, SK310

Validation date

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses

: Vaboratory use

: 11/28/2023

Container type: Bottle

GA051 // FLEX Monoclonal Mouse anti-Human Cytokeratin, HMW, Clone 34β E12 RTU (Omnis) // 12 mL

GA052 // FLEX Monoclonal Mouse anti-Human Melanosome, Clone HMB45 RTU (Omnis) // 12 mL

GA053 // FLEX Monoclonal Mouse anti-Human Cytokeratin, Clone AE1/AE3 (Omnis) //

GA054 // FLEX Monoclonal Mouse anti-Human Caldesmon, Clone h-CD (Omnis) // 12 mL

GA055 // /FLEX Monoclonal Mouse Anti-Human Wilms' Tumor 1 (WT1) // 12 ml Protein, Clone 6F-H2, RTU (Dako Omnis) // 12 mL

GA058 // /FLEX Monoclonal Mouse Anti-Human Inhibin $\dot{\epsilon}$, Clone R1, RTU (Dako Omnis) // 12 mL

GA059 // FLEX Monoclonal Mouse anti-Human E-Cadherin, Clone NCH-38 (Omnis) // 12 ml

GA060 // FLEX Monoclonal Rabbit anti-Human AMACR, Clone 13H4-38 (Omnis) // 12 ml

GA061 // FLEX Monoclonal Mouse anti-Human CD15, Clone Carb-3 (Omnis) // 12 mL GA062 // /FLEX Monoclonal Mouse Anti-Human CD15, Clone Carb-3, RTU (Dako Omnis) // 12 mL

GA067 // /FLEX Monoclonal Mouse Anti-Myogenin, Clone F5D, RTU (Dako Omnis) // 12 mL

GA074 // /FLEX Monoclonal Mouse Anti-Human Mammaglobin, Clone 304-1A5, RTU (Dako Omnis) // 12 mL

GA075 // /FLEX Monoclonal Mouse Anti-Human Renal Cell Carcinoma Marker, Clone SPM314, RTU (Dako Omnis) // 12 mL

GA077 // /FLEX Monoclonal Mouse Anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3, RTU (Dako Omnis) // 12 mL

GA080 // /FLEX Monoclonal Mouse Anti-Human CDX2, Clone DAK-CDX2, RTU (Dako Omnis) // 12 mL

GA083 // FLEX Monoclonal Rabbit Anti-Human Cyclin D1, Clone EP12, Ready-to-Use (Dako Omnis) // 12 mL

GA084 // /FLÉX Monoclonal Rabbit Anti-Human Estrogen Receptor ¿, Clone EP1, RTU (Dako Omnis) // 12 mL

GA090 // FLEX Monoclonal Mouse Anti-Human Progesterone Receptor Clone PgR

Date of issue: 11/28/2023 1/14

```
1294 RTU (Dako Omnis) // 12 mL
```

GA600 // /FLEX Universal Negative Control, Rabbit, RTU (Dako Omnis) // 12 mL

GA750 // FLEX Universal Negative Control Mouse RTU // 12 mL

IC001 // DuoFLEX Cocktail anti-S100 anti-Tyrosinase anti-Melan-A RTU (Link) // 6 mL

IC002 // DuoFLEX Cocktail anti-CD3 anti-CD20cy RTU (Link) // 6 mL

IC004 // DuoFLEX Cocktail anti-AMACR anti-Cytokeratin HMW anti-Cytokeratin 5/6 RTU (Link) // 6 mL

IK001 // DuoFLEX Cocktail anti-S100 anti-Tyrosinase anti-Melan-A RTU // 6 mL

IK002 // DuoFLEX Cocktail anti-CD3 anti-CD20cy RTU // 6 mL

IK004 // DuoFLEX Cocktail anti-AMACR anti-Cytokeratin HMW anti-Cytokeratin 5/6 RTU // 6 mL

IR002 // /FLEX Polyclonal Guinea Pig Anti-Insulin, RTU (Link) // 12 mL

IR051 // /FLEX Monoclonal Mouse Anti-Human Cytokeratin, High Molecular Weight, Clone 34ßE12, RTU (Link) // 12 mL

IR052 // FLEX Monoclonal Mouse anti-Human Melanosome, Clone HMB45 RTU (Link) // 12 mL

IR053 // FLEX Monoclonal Mouse anti-Human Cytokeratin, Clone AE1/AE3 RTU (Link) // 12 mL

IR054 // FLEX Monoclonal Mouse anti-Human Caldesmon, Clone h-CD RTU (Link) // 12 ml

IR055 // FLEX Monoclonal Mouse anti-Human Wilms' Tumor 1 (WT1) Protein, Clone 6F-H2 RTU (Link) // 12 mL

IR056 // FLEX Monoclonal Mouse anti-Thyroid Transcription Factor, TTF-1, Clone 8G7G3/1 RTU (Link) // 12 mL

IR057 // FLEX Monoclonal Mouse anti-Human CD99, MIC2 Ewing's Sarcoma Marker, Clone 12E7 RTU (Link) // 12 mL

IR058 // FLEX Monoclonal Mouse anti-Human Inhibin a, Clone R1 RTU (Link) // 12 mL IR059 // FLEX Monoclonal Mouse anti-Human E-Cadherin, Clone NCH-38 RTU (Link) // 12 mL

IR060 // FLEX Monoclonal Rabbit anti-Human AMACR, Clone 13H4 RTU (Link) // 12 mL IR061 // FLEX Monoclonal Mouse anti-Human Tyrosinase, Clone T311 RTU (Link) // 12 mL

IR062 // FLEX Monoclonal Mouse anti-Human CD15, Clone Carb-3 RTU (Link) // 12 mL IR066 // FLEX Monoclonal Mouse anti-Human Smooth Muscle Myosin Heavy Chain, Clone SMMS-1 RTU (Link) // 12 mL

IR067 // FLEX Monoclonal Mouse anti-Myogenin, Clone F5D RTU (Link) // 12 mL IR068 // FLEX Monoclonal Mouse anti-Human Progesterone Receptor, Clone PgR 636 RTU (Link) // 12 mL

IR069 // FLEX Monoclonal Mouse anti-Human CD1a, Clone 010 RTU (Link) // 12 mL IR072 // FLEX Monoclonal Mouse anti-Human Podoplanin, Clone D2-40 RTU (Link) // 12 mL

IR074 // FLEX Monoclonal Mouse anti-Human Mammaglobin, Clone 304-1A5 RTU (Link) // 12 mL

IR075 // FLEX Monoclonal Mouse anti-Human Renal Cell Carcinoma Marker, Clone SPM314 RTU (Link) // 12 mL

IR076 // FLEX Monoclonal Mouse anti-Villin, Clone 1D2 C3 RTU (Link) // 12 mL

IR077 // FLEX Monoclonal Mouse anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3 RTU (Link) // 12 mL

IR079 // FLEX Monoclonal Mouse anti-Human MutL Protein Homolog 1, Clone ES05 RTU (Link) // 12 mL

IR080 // FLEX Monoclonal Mouse anti-Human CDX2, Clone DAK-CDX2 RTU (Link) // 12 ml

IR082 // FLEX Monoclonal Mouse anti-Human CD5, Clone 4C7 RTU (Link) // 12 mL IR084 // FLEX Monoclonal Rabbit anti-Human Estrogen Receptor α , Clone EP1 RTU (Link) // 12 mL

IR085 // FLEX Monoclonal Mouse anti-Human MutS Protein Homolog 2, Clone FE11 RTU (Link) // 12 mL

IR086 // FLEX Monoclonal Rabbit anti-Human MutS Protein Homolog 6, Clone EP49 RTU (Link) // 12 mL

IR087 // FLEX Monoclonal Rabbit anti-Human Postmeitic Segregation Increased 2,

Date of issue : 11/28/2023 **2/14**

```
Clone EP51 RTU (Link) // 12 mL
```

IR088 // FLEX Monoclonal Mouse anti-Human Prostein, Clone 10E3 RTU (Link) // 12 mL IR089 // FLEX Monoclonal Mouse anti-Human Prostate Specific Membrane Antigen, Clone 3E6 RTU (Link) // 12 mL

IR091 // FLEX Monoclonal Mouse anti-Human ERCC1, Clone 4F9 RTU (Link) // 12 mL IR092 // FLEX Monoclonal Mouse Octamer-Binding Transcription Factor 3/4, Clone N1NK RTU (Link) // 12 mL

IR093 // FLEX Monoclonal Rabbit anti-Human Terminal Deoxynucleotidyl Transferase, Clone EP266 RTU (Link) // 12 mL

IR094 // FLEX Monoclonal Rabbit anti-Human Cytokeratin 8/18, Clone EP17/EP30 RTU (Link) // 12 mL

IR600 // FLEX Negative Control Rabbit Immunoglobulin Fraction of Serum from Non-immunized Rabbits RTU // 12 mL

IR750 // FLEX Negative Control Mouse Cocktail of Mouse, RTU (Link) / 12 mL IS051 // FLEX Monoclonal Mouse anti-Human Cytokeratin, HMW, Clone 34β E12 RTU // 6 mL

IS052 // FLEX Monoclonal Mouse anti-Human Melanosome, Clone HMB45 RTU // 6 mL IS053 // FLEX Monoclonal Mouse anti-Human Cytokeratin, Clone AE1/AE3 RTU // 6 mL IS054 // FLEX Monoclonal Mouse anti-Human Caldesmon, Clone h-CD RTU // 6 mL IS055 // FLEX Monoclonal Mouse anti-Human Wilms' Tumor 1 (WT1) Protein, Clone 6F-H2 RTU // 6 mL

IS056 // FLEX Monoclonal Mouse anti-Thyroid Transcription Factor, TTF-1, Clone 8G7G3/1 RTU // 6 mL

IS057 // FLEX Monoclonal Mouse anti-Human CD99, MIC2 Ewing's Sarcoma Marker, Clone 12E7 RTU // 6 mL

IS059 // FLEX Monoclonal Mouse anti-Human E-Cadherin, Clone NCH-38 RTU // 6 mL IS060 // FLEX Monoclonal Rabbit anti-Human AMACR, Clone 13H4 RTU // 6 mL IS062 // FLEX Monoclonal Mouse anti-Human CD15, Clone Carb-3 RTU // 6 mL IS067 // /FLEX Monoclonal Mouse Anti-Myogenin, Clone F5D, RTU (Dako Autostainer/

Autostainer Plus) // 6 mL IS068 // FLEX Monoclonal Mouse anti-Human Progesterone Receptor, Clone PgR 636 RTU // 6 mL

IS069 // FLEX Monoclonal Mouse anti-Human CD1a, Clone 010 RTU // 6 mL IS072 // FLEX Monoclonal Mouse anti-Human Podoplanin, Clone D2-40 RTU // 6 mL IS074 // FLEX Monoclonal Mouse anti-Human Mammaglobin, Clone 304-1A5 RTU // 6 mL

IS075 // FLEX Monoclonal Mouse anti-Human Renal Cell Carcinoma Marker, Clone SPM314 RTU // 6 mL

IS077 // FLEX Monoclonal Mouse anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3 RTU // 6 mL

IS079 // FLEX Monoclonal Mouse anti-Human MutL Protein Homolog 1, Clone ES05 RTU // $6\ mL$

IS080 // FLEX Monoclonal Mouse anti-Human CDX2, Clone DAK-CDX2 RTU // 6 mL IS082 // FLEX Monoclonal Mouse anti-Human CD5, Clone 4C7 RTU // 6 mL IS084 // FLEX Monoclonal Rabbit anti-Human Estrogen Receptor α , Clone EP1 RTU //

IS600 // FLEX Negative Control Rabbit Immunoglobulin Fraction of Serum from Non-immunized Rabbits RTU // 6 mL

IS750 // FLEX Negative Control Mouse Cocktail of Mouse, RTU // 6 mL

IX018 // Monoclonal Mouse Anti-Human Proinsulin, Clone 3B1 // 50 ml - 3 L

IX019 // Monoclonal Mo a Hu Proinsulin, Clone A6C9 // 50 ml - 3 L

K3954 // Biotinylation Reagent // Dako ARK (Animal Research Kit), Peroxidase // 1.5 mL

K3954 // Blocking Reagent // Dako ARK (Animal Research Kit), Peroxidase // 1.5 mL

M0617 // Monoclonal Mouse Anti-Thrombomodulin, Clone 1009 // 1 mL

M0630 // Monoclonal Mouse Anti-Human Cytokeratin, High Molecular Weight, Clone $34\beta E12$ // 1 mL

M0633 // Monoclonal Mouse Anti-Rabbit Macrophage, Clone RAM11 // 1 mL

M0634 // Monoclonal Mouse Anti-Human Melanosome, Clone HMB-45 // 0.2 ml, 1 ml

M0635 // Monoclonal Mouse Anti-Human Muscle Actin, Clone HHF35 // 1 mL

M3501 // Monoclonal Mouse Anti-Adrenocorticotropin (ACTH), Clone 02A3 // 1 mL

Date of issue: 11/28/2023 **3/14**

```
M3502 // Monoclonal Mouse Anti-Human Luteinizing Hormone (LH), Clone C93 // 1 mL M3503 // Monoclonal Mouse Anti-Human Thyroid-Stimulating Hormone (TSH), Clone 0042 // 1 mL
```

M3504 // Monoclonal Mouse Anti-Human Follicle-Stimulating Hormone (FSH), Clone C10 // 1 mL $\,$

M3505 // Monoclonal Mouse Anti-Human Mesothelial Cell, Clone HBME-1 // 1 mL M3506 // Monoclonal Mouse Anti-Hepatitis B Virus Surface Antigen (HBsAg) Clone 3E7

M3512 // Monoclonal Mouse Anti-Human MyoD1, Clone 5.8A // 1 mL

M3515 // Monoclonal Mouse Anti-Human Cytokeratin, Clone AE1 // AE3 // 0.2 mL, 1 mL

M3517 // Monoclonal Mouse Anti-CA 19-9, Clone 116-NS-19-9 // 1 mL

M3525 // Monoclonal Mouse Anti-Human Epithelial-Related Antigen, Clone MOC-31 // 1 $\,$ mL

M3528 // Monoclonal Mouse Anti-Human Papillomavirus (HPV), Clone K1H8 // 1 mL

M3539 // Monoclonal Mouse Anti-Human Beta-Catenin, Clone β -Catenin-1 // 1 mL

M3556 // Monoclonal Mouse Anti-Human Calponin, Clone CALP // 1 mL

M3562 // Monoclonal Mouse Anti-Human Androgen Receptor, Clone AR441 // 1 mL

M3563 // Monoclonal Mouse Anti-Human Epidermal Growth Factor Receptor, Clone H11 // 1 mL $\,$

M3567 // Monoclonal Mouse Anti-Human Fascin, Clone 55K-2 // 1 mL

M3568 // Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 1294 // 1 mL

M3569 // Monoclonal Mouse Anti-Human Progesterone Receptor, Clone PgR 636 // $0.2\,$ mL 1 mL

M3571 // Monoclonal Mouse Anti-Human CD1a, Clone O10 010 // 1 mL

M3575 // Monoclonal Mouse Anti-Thyroid Transcription Factor, Clone 8G7G3 // 1 // 0.2 mL, 1 mL

M3612 // Monoclonal Mouse Anti-Human E-Cadherin, Clone NCH-38 // 0.2 mL, 1 ml

M3614 // Monoclonal Mouse Anti-Human Thymidylate Synthase, Clone TS106 // 1 mL

M3615 // Monoclonal Mouse Anti-Human P501S Prostein, Clone 10E3 // 0.2 mL, 1 mL

M3616 // Monoclonal Rabbit Anti-Human P504S AMACR, Clone 13H4 // 0.2 mL, 1 mL

M3617 // Monoclonal Mouse Anti-Human COX-2, Clone CX-294 // 1 mL

M3619 // Monoclonal Mouse Anti-Human D2-40, Clone D2-40 // 0.2 mL, 1 mL

M3620 // Monoclonal Mouse Anti-Human Prostate-Specific Membrane Antigen, Clone 3E6 // 0.2 mL, 1 mL

M3621 // Monoclonal Mouse Anti-Human MITF, Clone D5 // 0.2 mL

M3623 // Monoclonal Mouse Anti-Human Tyrosinase, Clone T311 // 0.2 mL

M3624 // Monoclonal Mouse Anti-Human Survivin, Clone 12C4 // 0.2 mL

M3625 // Monoclonal Mouse Anti-Human Mammaglobin, Clone 304-1A5 // 0.2 mL

M3626 // Monoclonal Mouse Anti-Human L523S Protein IMP3. Clone 69.1 // 0.2 mL

M3627 // Monoclonal Mouse Anti-Human PTEN, Clone 6H2.1 // 0.2 mL

M3628 // Monoclonal Rabbit Anti-Human Akt-pS473, Phosphorylation Site Specific, Clone 14-5 // 1 mL

M3631 // Monoclonal Mouse Anti-Human CD15, Clone Carb-3 // 0.2 mL, 1 mL

M3632 // Monoclonal Mouse Anti-Human Renal Cell Carcinoma Marker, Clone SPM314 // 1 ml

M3636 // Monoclonal Mouse Anti-Human CDX2, Clone DAK-CDX2 // 0.2 mL, 1 mL

M3638 // Monoclonal Mouse Anti-Human Gross Cystic Disease Fluid Protein-15, Clone 23A3 // 1 mL

M3639 // Monoclonal Mouse Anti-Human MSH2, Clone FE11 // 0.2 mL, 1 mL

M3640 // Monoclonal Mouse Anti-Human MutL Protein Homolog 1, Clone ES05 // 0.2 mL, 1 mL

M3641 // Monoclonal Mouse Anti-Human CD5, Clone 4C7 // 1 mL

M3642 // Monoclonal Rabbit Anti-Human Cyclin D1, Clone EP12 // 1 mL

M3643 // Monoclonal Rabbit Anti-Human Estrogen Receptor \dot{c} , Clone EP1 // 0.2 mL, 1 ml

M3646 // Monoclonal Rabbit Anti-Human MutS Protein Homolog 6, Clone EP49 // $0.2\,$ mL, 1 mL

M3647 // Monoclonal Rabbit Anti-Human Postmeiotic Segregration Increased 2, Clone EP51 // 0.2 mL, 1 mL

Date of issue: 11/28/2023 4/14

M3649 // Monoclonal Mouse Anti-Human Octamer-Binding Transcription Factor 3 // 4, Clone N1NK // 0.2 mL, 1 mL

M3651 // Monoclonal Rabbit Anti-Human Terminal Deoxynucleotidyl Transferase (TdT), Clone EP266 // 1 mL

M3653// Monoclonal Mouse Anti-Human PD-L1 Clone 22C3 // 0.2 mL M3666// Monoclonal Mouse Anti-Human PD-L1, Clone 22C3/ 0.2mL

M7019 // Monoclonal Mouse Anti-Human Cytokeratin 20, Clone Ks20.8 // 0.2 mL, 1 mL

M7020 // Monoclonal Mouse Anti-Vimentin, Clone Vim 3B4 // 1 mL

M7191 // Monoclonal Mouse Anti-Human Placental Alkaline Phosphatase, Clone 8A9 // $0.2\ mL$, 1 mL

M7235 // Monoclonal Mouse Anti-Human Grannzyme B, Clone GrB-7 // 1 mL

M7237 // Monoclonal Mouse Anti-Human Cytokeratin 5 // 6, Clone D5 // 16 B4 // 0.2 mL, 1 ml

M7240 // Monoclonal Mouse Anti-Human Ki-67 Antigen, Clone MIB-1 // 0.2 mL, 1 mL

M7271 // Monoclonal Mouse Anti-Human CD57, Clone TB01 // 0.2 mL

M7310 // Monoclonal Mouse Anti-Human CD4, Clone 4B12 // 0.2 mL, 1 mL

SK310 // Mouse anti-Human ER Antibody Cocktail // ER/PR pharmDx Kit (Link) // 12 mL

SK310 // Mouse anti-Human PR Antibody // ER/PR pharmDx Kit (Link) // 12 mL

SK310 // Negative Control Reagent // ER/PR pharmDx Kit (Link) // 12 mL

Reference number: SDS347

1.3 Details of the supplier of the safety data sheet

Supplier/Manufacturer

: Agilent Technologies, Inc. 5301 Stevens Creek Blvd Santa Clara, CA 95051, USA

Tel: +1 800 227 9770

Agilent Technologies Singapore (International) Pte Ltd.

No. 1 Yishun Avenue 7 Singapore, 768923 Tel. (65) 6276 2622

Agilent Technologies Denmark ApS

Produktionsvej 42 2600 Glostrup, Denmark

Tel. +45 44 85 95 00

www.Agilent.com

e-mail address of person responsible for this SDS

: SDS@Agilent.com

1.4 Emergency telephone number

In case of emergency : CHEMTREC®: 1-800-424-9300

Section 2. Hazards identification

2.1 Classification of the substance or mixture

OSHA/HCS status

: While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture

Not classified.

Date of issue: 11/28/2023 5/14

Section 2. Hazards identification

Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic environment: 1%

2.2 GHS label elements

Signal word : No signal word.

Hazard statements : No known significant effects or critical hazards.

Precautionary statements

Prevention : Not applicable.

Response : Not applicable.

Storage : Not applicable.

Disposal : Not applicable.

2.3 Other hazards

Hazards not otherwise : None known.

classified

Section 3. Composition/information on ingredients

Substance/mixture : Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Section 4. First aid measures

4.1 Description of necessary first aid measures

Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower

eyelids. Check for and remove any contact lenses. Get medical attention if irritation

occurs.

Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get

medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under

medical surveillance for 48 hours.

Skin contact : Flush contaminated skin with plenty of water. Remove contaminated clothing and

shoes. Get medical attention if symptoms occur.

Ingestion: Wash out mouth with water. If material has been swallowed and the exposed person is

conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

4.2 Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact: No specific data.Inhalation: No specific data.Skin contact: No specific data.Ingestion: No specific data.

4.3 Indication of immediate medical attention and special treatment needed, if necessary

Date of issue: 11/28/2023 6/14

Section 4. First aid measures

Notes to physician

: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

Specific treatments

No specific treatment.

Protection of first-aiders

: No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing

: None known.

media

5.2 Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

: In a fire or if heated, a pressure increase will occur and the container may burst.

Hazardous thermal decomposition products : Decomposition products may include the following materials: carbon dioxide

carbon monoxide nitrogen oxides sulfur oxides phosphorus oxides

5.3 Advice for firefighters

Special protective actions for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.

For emergency responders:

If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For nonemergency personnel".

6.2 Environmental precautions

: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up

: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

11/28/2023 Date of issue: 7/14

Section 7. Handling and storage

7.1 Precautions for safe handling

Protective measures

Advice on general occupational hygiene

- : Put on appropriate personal protective equipment (see Section 8).
- : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

: Specific storage conditions: Please consult the label.

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations

: Industrial applications, Professional applications.

Industrial sector specific

solutions

: Not available.

Section 8. Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
None.	

Biological exposure indices

No exposure indices known.

8.2 Exposure controls

Appropriate engineering controls

Environmental exposure controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with sideshields.

Skin protection

Date of issue: 11/28/2023 **8/14**

Section 8. Exposure controls/personal protection

Hand protection

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties and safety characteristics

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

Physical state : Liquid. [Clear.]
Color : Colorless.
Odor : Odorless.
Odor threshold : Not available.

pH : 7.6

Melting point/freezing point : 0°C (32°F)

Boiling point, initial boiling : 100°C (212°F)

point, and boiling range

Flash point : Not available.
Evaporation rate : Not available.
Flammability : Not applicable.
Lower and upper explosion : Not available.

limit/flammability limit

Vapor pressure

	Vapor Pressure at 20°C			Vapor pressure at 50°C			
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
₩ater	17.5	2.3	-	92.258	12.3	-	

Relative vapor density Relative density

Not available.Not available.

Solubility(ies)

MediaResultwaterSoluble

Miscible with water

: Yes.

Partition coefficient: noctanol/water Not applicable.

Auto-ignition temperature

Viscosity

: Not available.: Not available.: Not available.

Particle characteristics

Decomposition temperature

Median particle size : Not applicable.

Date of issue: 11/28/2023 9/14

Section 10. Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions

: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : No specific data.

10.5 Incompatible materials : May react or be incompatible with oxidizing materials.

10.6 Hazardous decomposition products

: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Not available.

Irritation/Corrosion

Not available.

Sensitization

Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Reproductive toxicity

Conclusion/Summary: Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure

: Not available.

Potential acute health effects

Eye contact
 Inhalation
 No known significant effects or critical hazards.
 Skin contact
 Ingestion
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.
 No known significant effects or critical hazards.

Date of issue: 11/28/2023 **10/14**

Section 11. Toxicological information

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : No specific data.
Inhalation : No specific data.
Skin contact : No specific data.
Ingestion : No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Long term exposure

Potential immediate : Not available.

effects

Potential delayed effects : Not available.

Potential chronic health effects

General : No known significant effects or critical hazards.
 Carcinogenicity : No known significant effects or critical hazards.
 Mutagenicity : No known significant effects or critical hazards.
 Reproductive toxicity : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

N/A

Section 12. Ecological information

12.1 Toxicity

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition : Not available.

coefficient (Koc)

12.5 Other adverse effects : No known significant effects or critical hazards.

Date of issue : 11/28/2023 **11/14**

Section 13. Disposal considerations

13.1 Waste treatment methods

Disposal methods

: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

Section 14. Transport information

DOT / TDG / Mexico / IMDG / : Not regulated. **IATA**

Special precautions for user : Transport within user's premises: always transport in closed containers that are

upright and secure. Ensure that persons transporting the product know what to do in the

event of an accident or spillage.

Transport in bulk according : Not available.

to IMO instruments

Section 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

U.S. Federal regulations : TSCA 8(a) CDR Exempt/Partial exemption: Not determined

Clean Air Act Section 112 : Not listed

(b) Hazardous Air

Pollutants (HAPs)

Clean Air Act Section 602 : Not listed

Class I Substances

Clean Air Act Section 602 : Not listed

Class II Substances

DEA List I Chemicals : Not listed

(Precursor Chemicals)

DEA List II Chemicals : Not listed

(Essential Chemicals)

SARA 302/304

Composition/information on ingredients

Date of issue: 11/28/2023 **12/14**

Section 15. Regulatory information

			SARA 302 TPQ		SARA 304 RQ	
Name	%	EHS	(lbs)	(gallons)	(lbs)	(gallons)
Sodium azide	<0.1	Yes.	500	-	1000	-

SARA 304 RQ : 1020408.2 lbs / 463265.3 kg

SARA 311/312

Classification : Not applicable.

Composition/information on ingredients

No products were found.

State regulations

Massachusetts: None of the components are listed.New York: None of the components are listed.New Jersey: None of the components are listed.Pennsylvania: None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia : Not determined.

Canada : Not determined.

China : All components are listed or exempted.

Japan : Japan inventory (CSCL): Not determined.

Japan inventory (ISHL): Not determined.

New Zealand: Not determined.Philippines: Not determined.Republic of Korea: Not determined.Taiwan: Not determined.

Thailand : Not determined.
Turkey : Not determined.

United States : All components are active or exempted.

Viet Nam : Not determined.

Date of issue: 11/28/2023 **13/14**

Section 16. Other information

Procedure used to derive the classification

Classification	Justification		
Not classified.			

History

Date of issue/Date of

revision

Date of previous issue : 03/08/2022

Version : 7

Key to abbreviations : ATE = Acute Toxicity Estimate

BCF = Bioconcentration Factor

GHS = Globally Harmonized System of Classification and Labelling of Chemicals

IATA = International Air Transport Association

IBC = Intermediate Bulk Container

IMDG = International Maritime Dangerous Goods

LogPow = logarithm of the octanol/water partition coefficient

MARPOL = International Convention for the Prevention of Pollution From Ships, 1973

as modified by the Protocol of 1978. ("Marpol" = marine pollution)

N/A = Not available UN = United Nations

▼ Indicates information that has changed from previously issued version.

: 11/28/2023

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.

Date of issue: 11/28/2023 14/14